首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients.
【24h】

Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients.

机译:碳青霉烯耐药铜绿假单胞菌:影响非危重患者多药耐药性获得的因素。

获取原文
获取原文并翻译 | 示例
       

摘要

A cohort study was carried out on hospitalized adult non-critically ill patients (January 2003-December 2004) to identify factors associated with the acquisition of multidrug-resistant Pseudomonas aeruginosa (MDR-PA). A total of 246 non-critically patients were included, 162 (66%) who revealed MDR-PA in the first isolate and 84 (34%) who had carbapenem-resistant P. aeruginosa (CR-PA) isolates. Multivariate analysis identified nosocomial acquisition (odds ratio [OR] 2.7, 95% confidence interval [CI] 1.1-6.3), urinary catheter (OR 2.1, 95%CI 1.1-4.3), and the prior use of fluoroquinolones (OR 2.6, 95%CI 1.0-6.7) as independent risk factors associated with MDR-PA acquisition. Our results show that antibiotics, most notably, fluoroquinolones, may play a major role in the emergence of MDR-PA.
机译:对住院的成年非重症患者进行了一项队列研究(2003年1月至2004年12月),以确定与获得多药耐药的铜绿假单胞菌(MDR-PA)相关的因素。总共包括246名非危重患者,其中162名(66%)的患者在第一个隔离株中发现了MDR-PA,84名(34%)的患者具有对碳青霉烯耐药的铜绿假单胞菌(CR-PA)分离株。多变量分析确定了院内获取(赔率[OR] 2.7,95%置信区间[CI] 1.1-6.3),导尿管(OR 2.1,95%CI 1.1-4.3)以及先前使用的氟喹诺酮类药物(OR 2.6、95) %CI 1.0-6.7)作为与MDR-PA收购相关的独立风险因素。我们的结果表明,抗生素(最显着的是氟喹诺酮类)可能在MDR-PA的出现中起主要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号